

Glp-1 Receptor Agonist Market Outlook 2025-2034: Market Share, and Growth Analysis By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs), By Route Of Administration (Parenteral, Oral), By End Users

<https://marketpublishers.com/r/G200EFA2D7EAEN.html>

Date: October 2025

Pages: 160

Price: US\$ 3,950.00 (Single User License)

ID: G200EFA2D7EAEN

Abstracts

The Glp-1 Receptor Agonist Market is valued at USD 12 billion in 2025 and is projected to grow at a CAGR of 5.6% to reach USD 19.6 billion by 2034.

GLP-1 Receptor Agonist Market Overview

The GLP-1 receptor agonist market is experiencing robust expansion, driven by the growing prevalence of type 2 diabetes and obesity globally. These drugs, which mimic the glucagon-like peptide-1 hormone to enhance insulin secretion and suppress appetite, have become essential in the management of metabolic disorders. With increasing physician preference for GLP-1 receptor agonists due to their dual benefits—glycemic control and weight loss—the market is witnessing strong adoption rates. Pharmaceutical giants are intensifying their focus on this segment, resulting in a wave of product innovation and clinical pipeline development. The market is also gaining traction due to rising awareness about lifestyle diseases, improved diagnostic rates, and increasing healthcare spending, particularly in emerging economies. As treatment guidelines continue to evolve, GLP-1 receptor agonists are being recommended earlier in the disease management cycle, expanding their patient base and fueling market demand. The GLP-1 receptor agonist market saw significant developments, notably the rapid adoption of next-generation once-weekly and oral formulations. Novo Nordisk's and Eli Lilly's expanded indications for their blockbuster drugs, including weight management in non-diabetic obese patients, have opened up lucrative new market segments. Additionally, advancements in drug delivery

mechanisms and favorable clinical outcomes have further reinforced the efficacy and safety profile of these therapies, enhancing physician and patient confidence. Strategic partnerships and licensing agreements between pharmaceutical companies and biotech innovators accelerated drug development and regulatory approvals across key markets such as the U.S., EU, and Japan. Reimbursement policies also saw favorable updates, especially for obesity-related therapies, helping increase patient access. The year marked a turning point in positioning GLP-1 receptor agonists not just as diabetes medications but as comprehensive metabolic health solutions. The GLP-1 receptor agonist market is poised for transformative growth, with strong momentum expected in both diabetic and non-diabetic segments. Several late-stage pipeline drugs with enhanced efficacy and lower side-effect profiles are anticipated to receive regulatory greenlights, expanding therapeutic choices. Moreover, combination therapies pairing GLP-1 receptor agonists with other drug classes are in development, promising superior outcomes. With obesity being increasingly recognized as a chronic disease requiring long-term treatment, healthcare systems worldwide are expected to incorporate these drugs into broader preventive care models. Digital health integrations and AI-driven patient monitoring tools may also complement GLP-1 therapies by personalizing dosage and adherence strategies. Furthermore, geographic expansion into underpenetrated markets such as Latin America, Southeast Asia, and the Middle East will drive future volume growth, supported by investments in local manufacturing and distribution partnerships.

Key Insights Glp-1 Receptor Agonist Market

Growing off-label use of GLP-1 receptor agonists for obesity management is reshaping the market beyond its traditional diabetes focus, attracting a younger, health-conscious population seeking weight loss therapies.

Pharmaceutical companies are increasingly focusing on oral GLP-1 formulations to improve convenience and patient adherence, reducing dependency on injectable therapies.

Biopharmaceutical collaborations are accelerating innovation in multi-receptor agonists, combining GLP-1 with GIP and glucagon receptor agonists for enhanced metabolic effects.

Integration of digital therapeutics with GLP-1 treatment plans is emerging, allowing real-time monitoring of glucose and weight metrics for better disease management.

Shift in regulatory frameworks is broadening the approved uses of GLP-1 drugs, including cardiovascular risk reduction and liver disease treatments, expanding market applicability.

Rising global incidence of obesity and type 2 diabetes is increasing the need for effective long-term therapeutic interventions like GLP-1 receptor agonists.

Strong clinical evidence supporting weight loss and cardiovascular benefits is boosting physician confidence and encouraging early adoption in treatment pathways.

Favorable reimbursement policies and government support for chronic disease management are enhancing patient affordability and market accessibility.

Continued R&D investment by leading pharmaceutical companies is resulting in breakthrough drug formulations with better tolerability and longer action duration.

High cost of GLP-1 receptor agonist therapies remains a barrier to widespread adoption, particularly in low- and middle-income regions, limiting equitable access to these advanced treatments.

Glp-1 Receptor Agonist Market Segmentation

By Drug Class

Exenatide

Liraglutide

Dulaglutide

Lixisenatide

Other Drugs

By Route Of Administration

Parenteral

Oral

By End Users

Hospitals

Surgical Clinics

Other Users

Key Companies Analysed

Novo Nordisk A/S

Sanofi SA

Eli Lilly and Company

AstraZeneca Inc.

Boehringer Ingelheim International GmbH

Hanmi Pharm Co. Ltd.

Pfizer Inc.

Amgen Inc.

Innovent Biologics Inc.

Jiangsu Hengrui Medicine Co.

Sun Pharmaceuticals Industries Ltd.

9 Meters Biopharma Inc.

Intarcia Therapeutics Inc.

Amylin Pharmaceuticals Inc.

PegBio Co. Ltd.

Zealand Pharma A/S

Bristol-Myers Squibb Company

Chongqing Lummy Pharmaceutical Co. Ltd.

CymaBay Therapeutics Inc.

Daiichi Sankyo Company Limited

Dong-A ST Co. Ltd.

Eisai Co. Ltd.

Genentech Inc.

GlaxoSmithKline plc

HanAll Biopharma Co. Ltd.

Ipsen SA

Johnson & Johnson

Kowa Company Ltd.

LG Chem Ltd.

Ligand Pharmaceuticals Incorporated

Merck & Co. Inc.

Novartis AG .

Glp-1 Receptor Agonist Market Analytics

The report employs rigorous tools, including Porter's Five Forces, value chain mapping, and scenario-based modeling, to assess supply–demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behavior are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Glp-1 Receptor Agonist Market Competitive Intelligence

The competitive landscape is mapped through OG Analysis' proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.

Countries Covered

North America — Glp-1 Receptor Agonist market data and outlook to 2034

United States

Canada

Mexico

Europe — Glp-1 Receptor Agonist market data and outlook to 2034

Germany

United Kingdom

France

Italy

Spain

BeNeLux

Russia

Sweden

Asia-Pacific — Glp-1 Receptor Agonist market data and outlook to 2034

China

Japan

India

South Korea

Australia

Indonesia

Malaysia

Vietnam

Middle East and Africa — Glp-1 Receptor Agonist market data and outlook to 2034

Saudi Arabia

South Africa

Iran

UAE

Egypt

South and Central America — Glp-1 Receptor Agonist market data and outlook to 2034

Brazil

Argentina

Chile

Peru

** We can include data and analysis of additional countries on demand.*

Research Methodology

This study combines primary inputs from industry experts across the Glp-1 Receptor Agonist value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

What is the current and forecast market size of the Glp-1 Receptor Agonist industry at global, regional, and country levels?

Which types, applications, and technologies present the highest growth

potential?

How are supply chains adapting to geopolitical and economic shocks?

What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?

Who are the leading players, and how are their strategies evolving in the face of global uncertainty?

Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?

Where are the most investable opportunities—across technology roadmaps, sustainability-linked innovation, and M&A—and what is the best segment to invest over the next 3–5 years?

Your Key Takeaways from the Glp-1 Receptor Agonist Market Report

Global Glp-1 Receptor Agonist market size and growth projections (CAGR), 2024-2034

Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Glp-1 Receptor Agonist trade, costs, and supply chains

Glp-1 Receptor Agonist market size, share, and outlook across 5 regions and 27 countries, 2023-2034

Glp-1 Receptor Agonist market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034

Short- and long-term Glp-1 Receptor Agonist market trends, drivers, restraints, and opportunities

Porter’s Five Forces analysis, technological developments, and Glp-1 Receptor Agonist supply chain analysis

Glp-1 Receptor Agonist trade analysis, Glp-1 Receptor Agonist market price

analysis, and Glp-1 Receptor Agonist supply/demand dynamics

Profiles of 5 leading companies—overview, key strategies, financials, and products

Latest Glp-1 Receptor Agonist market news and developments

Additional Support

With the purchase of this report, you will receive

An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.

7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.

Complimentary report update to incorporate the latest available data and the impact of recent market developments.

** The updated report will be delivered within 3 working days*

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SUMMARY, 2025

- 2.1 Glp-1 Receptor Agonist Industry Overview
 - 2.1.1 Global Glp-1 Receptor Agonist Market Revenues (In US\$ billion)
- 2.2 Glp-1 Receptor Agonist Market Scope
- 2.3 Research Methodology

3. GLP-1 RECEPTOR AGONIST MARKET INSIGHTS, 2024-2034

- 3.1 Glp-1 Receptor Agonist Market Drivers
- 3.2 Glp-1 Receptor Agonist Market Restraints
- 3.3 Glp-1 Receptor Agonist Market Opportunities
- 3.4 Glp-1 Receptor Agonist Market Challenges
- 3.5 Tariff Impact on Global Glp-1 Receptor Agonist Supply Chain Patterns

4. GLP-1 RECEPTOR AGONIST MARKET ANALYTICS

- 4.1 Glp-1 Receptor Agonist Market Size and Share, Key Products, 2025 Vs 2034
- 4.2 Glp-1 Receptor Agonist Market Size and Share, Dominant Applications, 2025 Vs 2034
- 4.3 Glp-1 Receptor Agonist Market Size and Share, Leading End Uses, 2025 Vs 2034
- 4.4 Glp-1 Receptor Agonist Market Size and Share, High Growth Countries, 2025 Vs 2034
- 4.5 Five Forces Analysis for Global Glp-1 Receptor Agonist Market
 - 4.5.1 Glp-1 Receptor Agonist Industry Attractiveness Index, 2025
 - 4.5.2 Glp-1 Receptor Agonist Supplier Intelligence
 - 4.5.3 Glp-1 Receptor Agonist Buyer Intelligence
 - 4.5.4 Glp-1 Receptor Agonist Competition Intelligence
 - 4.5.5 Glp-1 Receptor Agonist Product Alternatives and Substitutes Intelligence
 - 4.5.6 Glp-1 Receptor Agonist Market Entry Intelligence

5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET STATISTICS – INDUSTRY

REVENUE, MARKET SHARE, GROWTH TRENDS AND FORECAST BY SEGMENTS, TO 2034

- 5.1 World Glp-1 Receptor Agonist Market Size, Potential and Growth Outlook, 2024-2034 (\$ billion)
- 5.1 Global Glp-1 Receptor Agonist Sales Outlook and CAGR Growth By Drug Class, 2024- 2034 (\$ billion)
- 5.2 Global Glp-1 Receptor Agonist Sales Outlook and CAGR Growth By Route Of Administration, 2024- 2034 (\$ billion)
- 5.3 Global Glp-1 Receptor Agonist Sales Outlook and CAGR Growth By End Users, 2024- 2034 (\$ billion)
- 5.4 Global Glp-1 Receptor Agonist Market Sales Outlook and Growth by Region, 2024-2034 (\$ billion)

6. ASIA PACIFIC GLP-1 RECEPTOR AGONIST INDUSTRY STATISTICS – MARKET SIZE, SHARE, COMPETITION AND OUTLOOK

- 6.1 Asia Pacific Glp-1 Receptor Agonist Market Insights, 2025
- 6.2 Asia Pacific Glp-1 Receptor Agonist Market Revenue Forecast By Drug Class, 2024- 2034 (USD billion)
- 6.3 Asia Pacific Glp-1 Receptor Agonist Market Revenue Forecast By Route Of Administration, 2024- 2034 (USD billion)
- 6.4 Asia Pacific Glp-1 Receptor Agonist Market Revenue Forecast By End Users, 2024-2034 (USD billion)
- 6.5 Asia Pacific Glp-1 Receptor Agonist Market Revenue Forecast by Country, 2024-2034 (USD billion)
 - 6.5.1 China Glp-1 Receptor Agonist Market Size, Opportunities, Growth 2024- 2034
 - 6.5.2 India Glp-1 Receptor Agonist Market Size, Opportunities, Growth 2024- 2034
 - 6.5.3 Japan Glp-1 Receptor Agonist Market Size, Opportunities, Growth 2024- 2034
 - 6.5.4 Australia Glp-1 Receptor Agonist Market Size, Opportunities, Growth 2024- 2034

7. EUROPE GLP-1 RECEPTOR AGONIST MARKET DATA, PENETRATION, AND BUSINESS PROSPECTS TO 2034

- 7.1 Europe Glp-1 Receptor Agonist Market Key Findings, 2025
- 7.2 Europe Glp-1 Receptor Agonist Market Size and Percentage Breakdown By Drug Class, 2024- 2034 (USD billion)
- 7.3 Europe Glp-1 Receptor Agonist Market Size and Percentage Breakdown By Route Of Administration, 2024- 2034 (USD billion)

7.4 Europe Glp-1 Receptor Agonist Market Size and Percentage Breakdown By End Users, 2024- 2034 (USD billion)

7.5 Europe Glp-1 Receptor Agonist Market Size and Percentage Breakdown by Country, 2024- 2034 (USD billion)

7.5.1 Germany Glp-1 Receptor Agonist Market Size, Trends, Growth Outlook to 2034

7.5.2 United Kingdom Glp-1 Receptor Agonist Market Size, Trends, Growth Outlook to 2034

7.5.2 France Glp-1 Receptor Agonist Market Size, Trends, Growth Outlook to 2034

7.5.2 Italy Glp-1 Receptor Agonist Market Size, Trends, Growth Outlook to 2034

7.5.2 Spain Glp-1 Receptor Agonist Market Size, Trends, Growth Outlook to 2034

8. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, GROWTH TRENDS, AND FUTURE PROSPECTS TO 2034

8.1 North America Snapshot, 2025

8.2 North America Glp-1 Receptor Agonist Market Analysis and Outlook By Drug Class, 2024- 2034 (\$ billion)

8.3 North America Glp-1 Receptor Agonist Market Analysis and Outlook By Route Of Administration, 2024- 2034 (\$ billion)

8.4 North America Glp-1 Receptor Agonist Market Analysis and Outlook By End Users, 2024- 2034 (\$ billion)

8.5 North America Glp-1 Receptor Agonist Market Analysis and Outlook by Country, 2024- 2034 (\$ billion)

8.5.1 United States Glp-1 Receptor Agonist Market Size, Share, Growth Trends and Forecast, 2024- 2034

8.5.1 Canada Glp-1 Receptor Agonist Market Size, Share, Growth Trends and Forecast, 2024- 2034

8.5.1 Mexico Glp-1 Receptor Agonist Market Size, Share, Growth Trends and Forecast, 2024- 2034

9. SOUTH AND CENTRAL AMERICA GLP-1 RECEPTOR AGONIST MARKET DRIVERS, CHALLENGES, AND FUTURE PROSPECTS

9.1 Latin America Glp-1 Receptor Agonist Market Data, 2025

9.2 Latin America Glp-1 Receptor Agonist Market Future By Drug Class, 2024- 2034 (\$ billion)

9.3 Latin America Glp-1 Receptor Agonist Market Future By Route Of Administration, 2024- 2034 (\$ billion)

9.4 Latin America Glp-1 Receptor Agonist Market Future By End Users, 2024- 2034 (\$

billion)

9.5 Latin America Glp-1 Receptor Agonist Market Future by Country, 2024- 2034 (\$ billion)

9.5.1 Brazil Glp-1 Receptor Agonist Market Size, Share and Opportunities to 2034

9.5.2 Argentina Glp-1 Receptor Agonist Market Size, Share and Opportunities to 2034

10. MIDDLE EAST AFRICA GLP-1 RECEPTOR AGONIST MARKET OUTLOOK AND GROWTH PROSPECTS

10.1 Middle East Africa Overview, 2025

10.2 Middle East Africa Glp-1 Receptor Agonist Market Statistics By Drug Class, 2024-2034 (USD billion)

10.3 Middle East Africa Glp-1 Receptor Agonist Market Statistics By Route Of Administration, 2024- 2034 (USD billion)

10.4 Middle East Africa Glp-1 Receptor Agonist Market Statistics By End Users, 2024-2034 (USD billion)

10.5 Middle East Africa Glp-1 Receptor Agonist Market Statistics by Country, 2024-2034 (USD billion)

10.5.1 Middle East Glp-1 Receptor Agonist Market Value, Trends, Growth Forecasts to 2034

10.5.2 Africa Glp-1 Receptor Agonist Market Value, Trends, Growth Forecasts to 2034

11. GLP-1 RECEPTOR AGONIST MARKET STRUCTURE AND COMPETITIVE LANDSCAPE

11.1 Key Companies in Glp-1 Receptor Agonist Industry

11.2 Glp-1 Receptor Agonist Business Overview

11.3 Glp-1 Receptor Agonist Product Portfolio Analysis

11.4 Financial Analysis

11.5 SWOT Analysis

12 APPENDIX

12.1 Global Glp-1 Receptor Agonist Market Volume (Tons)

12.1 Global Glp-1 Receptor Agonist Trade and Price Analysis

12.2 Glp-1 Receptor Agonist Parent Market and Other Relevant Analysis

12.3 Publisher Expertise

12.2 Glp-1 Receptor Agonist Industry Report Sources and Methodology

I would like to order

Product name: Glp-1 Receptor Agonist Market Outlook 2025-2034: Market Share, and Growth Analysis By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs), By Route Of Administration (Parenteral, Oral), By End Users

Product link: <https://marketpublishers.com/r/G200EFA2D7EAEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G200EFA2D7EAEN.html>